Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Echinococcus multilocularis | inhibitor of apoptosis protein | 0.0062 | 0.1084 | 0.1084 |
Trypanosoma cruzi | Eukaryotic initiation factor 4A-1 | 0.0327 | 1 | 0.5 |
Mycobacterium tuberculosis | Probable cold-shock DeaD-box protein A homolog DeaD (ATP-dependent RNA helicase dead homolog) | 0.0327 | 1 | 0.5 |
Echinococcus multilocularis | nmda type glutamate receptor | 0.0033 | 0.0108 | 0.0108 |
Echinococcus multilocularis | eukaryotic initiation factor 4A III | 0.0327 | 1 | 1 |
Trichomonas vaginalis | DEAD box ATP-dependent RNA helicase, putative | 0.0327 | 1 | 0.5 |
Trypanosoma cruzi | Eukaryotic initiation factor 4A-1 | 0.0327 | 1 | 0.5 |
Toxoplasma gondii | eukaryotic initiation factor-4A, putative | 0.0327 | 1 | 0.5 |
Plasmodium vivax | RNA helicase-1, putative | 0.0327 | 1 | 0.5 |
Schistosoma mansoni | inhibitor of apoptosis protein | 0.0062 | 0.1084 | 0.1084 |
Schistosoma mansoni | hypothetical protein | 0.0062 | 0.1084 | 0.1084 |
Schistosoma mansoni | DEAD box ATP-dependent RNA helicase | 0.0327 | 1 | 1 |
Echinococcus granulosus | inhibitor of apoptosis protein | 0.0062 | 0.1084 | 0.1084 |
Trichomonas vaginalis | DEAD box ATP-dependent RNA helicase, putative | 0.0327 | 1 | 0.5 |
Treponema pallidum | ATP-dependent RNA helicase | 0.0327 | 1 | 0.5 |
Entamoeba histolytica | DEAD/DEAH box helicase, putative | 0.0327 | 1 | 0.5 |
Leishmania major | eukaryotic initiation factor 4a, putative | 0.0327 | 1 | 0.5 |
Onchocerca volvulus | Eukaryotic initiation factor 4A homolog | 0.0327 | 1 | 1 |
Giardia lamblia | Translation initiation factor eIF-4A, putative | 0.0327 | 1 | 0.5 |
Leishmania major | eukaryotic initiation factor 4a, putative | 0.0327 | 1 | 0.5 |
Echinococcus multilocularis | eukaryotic initiation factor 4A | 0.0327 | 1 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0327 | 1 | 1 |
Echinococcus multilocularis | Glutamate receptor, ionotropic kainate 3 | 0.0033 | 0.0108 | 0.0108 |
Plasmodium falciparum | eukaryotic initiation factor 4A | 0.0327 | 1 | 0.5 |
Echinococcus granulosus | nmda type glutamate receptor | 0.0033 | 0.0108 | 0.0108 |
Echinococcus granulosus | eukaryotic initiation factor 4A III | 0.0327 | 1 | 1 |
Trypanosoma brucei | Eukaryotic initiation factor 4A-1 | 0.0327 | 1 | 0.5 |
Schistosoma mansoni | DEAD box ATP-dependent RNA helicase | 0.0327 | 1 | 1 |
Echinococcus granulosus | eukaryotic initiation factor 4A | 0.0327 | 1 | 1 |
Echinococcus multilocularis | baculoviral IAP repeat containing protein | 0.0062 | 0.1084 | 0.1084 |
Trichomonas vaginalis | DEAD box ATP-dependent RNA helicase, putative | 0.0327 | 1 | 0.5 |
Echinococcus granulosus | baculoviral IAP repeat containing protein | 0.0062 | 0.1084 | 0.1084 |
Schistosoma mansoni | inhibitor of apoptosis (iap) domain family member | 0.0062 | 0.1084 | 0.1084 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Diet (functional) | ND 0 % | In vivo Sterol lowering activity at dose as 0.10 % of the diet;ND means no data. | ChEMBL. | 6604816 |
Diet (functional) | ND 0 % | In vivo Triglyceride lowering activity at dose as 0.10 % of the diet;ND means no data. | ChEMBL. | 6604816 |
Diet (functional) | = 78 % | In vivo Triglyceride lowering activity at dose as 0.03 % of the diet. | ChEMBL. | 6604816 |
Diet (functional) | = 94 % | In vivo triglyceride lowering activity, dosed at 0.01 % of the diet. | ChEMBL. | 6604816 |
Diet (functional) | = 98 % | In vivo Sterol lowering activity at dose as 0.03 % of the diet. | ChEMBL. | 6604816 |
Diet (functional) | = 104 % | In vivo Sterol lowering activity at dose as 0.01 % of the diet. | ChEMBL. | 6604816 |
Inhibition (binding) | = 44 % | In vitro inhibitory activity against acyl coenzyme A:cholesterol acyltransferase (ACAT) | ChEMBL. | 6604816 |
Inhibition (binding) | = 44 % | In vitro inhibitory activity against acyl coenzyme A:cholesterol acyltransferase (ACAT) | ChEMBL. | 6604816 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.